MicroConstants China

MicroConstants China in-licenses liver cancer drug from Pertinax Therapeutics

Monday, September 9, 2013

Site management organization and CRO MicroConstants China will in-license the China rights for a phase II liver cancer drug, PTX-9908, from Pertinax Therapeutics of Canada. MicroConstants China will be responsible for funding clinical development of PTX-9908 in China. Pertinax will receive a royalty in connection with sales, as well as any future assignment or transfer of the rights.

[Read More]